Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)Business Wire • 11/18/25
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026Zacks Investment Research • 11/17/25
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/17/25
Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of NovemberSeeking Alpha • 11/17/25
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTXBusiness Wire • 11/16/25
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium TranscriptSeeking Alpha • 11/14/25
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happyMarket Watch • 11/14/25
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics DealInvestors Business Daily • 11/14/25
Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approachesInvezz • 11/14/25
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral AgentBusiness Wire • 11/14/25